131
Participants
Start Date
October 2, 2018
Primary Completion Date
September 22, 2020
Study Completion Date
September 22, 2020
Edasalonexent
100 mg/kg/day
Placebo
Placebo
Children's University Hospital, Dublin
The Children's Hospital at Westmead, Westmead
Royal Children's Hospital, Parkville
Children's Health Queensland Children's Hospital and Health Service, South Brisbane
Children's Hospital of Philadelphia, Philadelphia
University of Hamburg, Hamburg
Kennedy Krieger Institute, Baltimore
Johns Hopkins School of Medicine, Baltimore
Children's Hospital of Richmond at VCU, Richmond
Children's Hospital of the King's Daughters, Norfolk
Rare Disease Research, LLC, Atlanta
Nemours Children's Hospital, Orlando
Vanderbilt University Medical Center, Nashville
Queen Silvia Children's Hospital, Gothenburg
MetroHealth Medical Center, Cleveland
Cincinnati Children's Hospital, Cincinnati
University of Michigan, Ann Arbor
University of Iowa Children's Hospital, Iowa City
University of Minnesota, Minneapolis
Rush University Children's Hospital, Chicago
University of Kansas Medical Center, Fairway
Arkansas Children's Hospital, Little Rock
Cook Children's Medical Center, Fort Worth
University of Texas Health Science Center at San Antonio, San Antonio
University of Munich, Munich
University of Utah, Salt Lake City
Las Vegas Clinic, Las Vegas
Children's Hospital of Los Angeles, Los Angeles
UC Davis, Sacramento
Shriners Hospitals for Children, Portland
Hadassah Medical Center, Jerusalem
Boston Children's Hospital, Boston
Alberta Children's Hospital, Calgary
London Health Sciences Centre - Children's Hospital, London
Children's Hospital of Eastern Ontario, Ottawa
CHU Sainte-Justine, Montreal
Bristol Children's Hospital, Bristol
Evelina Children's Hospital, London
Great Ormond Street Hospital (GOSH), London
Royal Manchester Children's Hospital, Manchester
Lead Sponsor
Catabasis Pharmaceuticals
INDUSTRY